secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tevogen Bio Holdings Inc. (TVGN)
CIK:        0001860871
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0001493152-24-016060
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tevogen Bio expects to eliminate $94.9M liabilities via note conversion; launches AI initiative, appoints new leaders
--------------------------------------------------------------------------------

- Expects to report $94.9M liability elimination from conversion of promissory notes into common stock.
- Pro forma balance sheet shows no remaining convertible note liabilities; $80.7M current and $14.2M long-term removed.
- Operating expenses for Tevogen Bio Inc. in 2023 were $8.8M, primarily non-cash charges from note fair value changes.
- Launches Tevogen.ai AI initiative to enhance drug discovery, manufacturing, and patient access; Mittul Mehta appointed CIO.
- Appoints Tapan V. Shah as Head of Investor Relations and Corporate Development; 25-year Wall Street veteran.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860871/000149315224016060/0001493152-24-016060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860871/000149315224016060/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-016060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer